No Data
No Data
Lucid Capital Initiates CalciMedica(CALC.US) With Buy Rating, Announces Target Price $13
Insider Purchase: Director at $CALC (CALC) Buys 4,800 Shares
Comprehensive 2024 Insights Into the Acute Pancreatitis Pipeline Treatment Landscape Featuring CalciMedica, SCM Lifescience, and Lamassu Pharma
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
CalciMedica Announces Presentations at Upcoming Medical Meetings
CalciMedica | 10-Q: Q3 2024 Earnings Report
No Data
73264095 : Nice, thanks! You think UMAC is done? looked like it held up pretty well in AH
Jaguar8 OP 73264095 : Nope. I feel it will still go
Jaguar8 OP 73264095 : I have not yet finished the list
Huaw : Will the rejection of APLT approval cause such a significant decline? Is it this serious?
Jaguar8 OP Huaw : It was just a CRL meaning they can’t approve at the moment due to some deficiencies which the company will address and will resubmit
View more comments...